Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAclarion Inc

Aclarion Inc

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
1.67 USD 0.01 ( 0.60%)
Last update at 2026-11-09T15:41:00Z
VOLUME
7331
Market Cap
8.06M

Momentum Score

…

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.67
Low
1.72
High
52 Week Price Range
2.34
Low
12.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Aclarion Inc (ACON) is limited; the company has provided only brief disclosures and does not have a clearly described operating business in widely available filings. Because substantive details on industry, products or customers are sparse, potential long-term growth drivers are not publicly verifiable and investors should consult SEC filings and company presentations to assess whether the planned strategy could support revenue and margin expansion.
The primary investment risk is the paucity of public disclosures, which increases uncertainty about the firm's business model, financial condition, execution capacity and liquidity and requires close monitoring of future filings and announcements.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.66
Dividend Yield
-
Revenue TTM
0.08M
Revenue Per Share
0.14
Gross Profit TTM
0.01M
Debt / Equity
-1.55
ROE
-104.80%
Net Debt
-12015789.00M
ROCE
-0.00%
Diluted EPS TTM
-13.61

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.23M -6.99M -4.91M -7.61M -4.95M
Net income -7.23M -6.99M -4.91M -9.11M -3.53M
Selling general administrative 4124832.00M 3.61M 3.25M 4.47M 1.83M
Selling and marketing expenses 1900598.00M 0.98M 0.76M 0.54M 0.33M
Gross profit -0.22M -0.08M -0.00M -0.00M -0.01M
Reconciled depreciation 0.23M 0.19M 0.16M 0.19M 0.19M
Ebit -7.05M -6.46M -4.30M -6.10M -2.95M
Ebitda -6.82M -6.26M -4.14M -5.90M -4.66M
Depreciation and amortization 0.23M 0.19M 0.16M 0.20M -1.70M
Operating income -7.05M -5.51M -4.88M -6.10M -2.95M
Other operating expenses 7.13M 5.56M 4.95M 6.16M 3.01M
Interest expense 0.00M 0.54M 0.61M 1.51M 0.48M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.41M 0.00M 0.00M 0.00M -
Net interest income 0.41M -0.54M -0.61M -1.51M -0.48M
Income tax expense - 0.00M -0.00M 1.51M -1.42M
Total revenue 0.08M 0.05M 0.08M 0.06M 0.06M
Total operating expenses 6.83M 5.43M 4.88M 6.09M 2.94M
Cost of revenue 0.30M 0.13M 0.08M 0.07M 0.07M
Total other income expense net -0.18M -1.48M -0.04M -1.51M -2.00M
Net income from continuing ops -7.23M -6.99M -4.91M -7.61M -4.95M
Net income applicable to common shares - - - -7.48M -5.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13672404.00M 2.12M 2.46M 3.21M 1.89M
Intangible assets 1251531.00M 1.29M 1.17M 1.21M 1.14M
Other current assets 380914.97M 0.35M 0.14M 0.20M 0.27M
Total liab 837287.00M 1.15M 3.19M 1.42M 7.62M
Total stockholder equity 12835117.00M 0.97M -0.73M 1.79M -5.73M
Other current liab 837286.67M 0.62M 1.30M 0.96M 4.56M
Common stock 9.00M - 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -58495940.00M -51.26M -44.28M -39.91M -31.89M
Other assets - - 0.00M 0.00M -
Cash 12015789.00M 0.45M 1.03M 1.47M 0.45M
Total current liabilities 837287.00M 1.15M 3.19M 1.42M 7.62M
Net debt -12015789.00M -0.45M 0.09M -1.47M 1.55M
Short term debt - - 1.13M - 2.00M
Short long term debt - - 1.13M - 2.00M
Short long term debt total - - 1.13M - 2.00M
Other stockholder equity 71331119.33M 52.23M 43.55M 41.69M 26.16M
Property plant equipment - - - 0.00M 0.01M
Total current assets 12396704.00M 0.82M 1.19M 1.99M 0.73M
Net tangible assets - - - 1.02M -13.98M
Short term investments - 0.04M - - -
Net receivables 0.03M 0.02M 0.01M 0.02M 0.01M
Inventory - - 0.00M 0.30M -
Accounts payable 0.33M 0.53M 0.76M 0.46M 1.06M
Non currrent assets other - - 0.10M - -
Non current assets total 1275700.00M 1.30M 1.27M 1.22M 1.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.32M -0.12M -0.21M -0.15M
Change to liabilities - - - -0.60M 0.20M
Total cashflows from investing activities -203902.00M -0.32M -0.12M -0.21M -0.15M
Net borrowings 0.00M -0.30M 2.25M -2.00M 2.94M
Total cash from financing activities 18945234.00M 5.03M 3.31M 6.55M 2.94M
Change to operating activities - - - -0.00M 0.46M
Net income -7233629.00M -6.99M -4.91M -7.61M -4.95M
Change in cash 11577128.00M -0.57M -0.45M 1.03M 0.44M
Begin period cash flow 463661.00M 1.03M 1.48M 0.45M 0.01M
End period cash flow 12040789.00M 0.46M 1.03M 1.48M 0.45M
Total cash from operating activities -7164204.00M -5.27M -3.65M -5.31M -2.35M
Issuance of capital stock 20.26M 6.57M 1.46M 8.55M -
Depreciation 227406.00M 0.19M 0.16M 0.19M 0.19M
Other cashflows from investing activities -203901.80M -0.32M -0.12M - -
Dividends paid 5425.00M 0.06M - 0.42M -
Change to account receivables -0.01M 0.01M -0.00M -0.01M 0.02M
Sale purchase of stock -1.21M 0.00M -0.00M - -
Other cashflows from financing activities 18950640.05M -0.25M -0.40M 0.42M -0.15M
Change to netincome - - - 2.59M 1.73M
Capital expenditures 0.02M 0.32M 0.12M 0.21M 0.15M
Change in working capital -0.36M -0.56M 0.62M 0.81M 0.68M
Stock based compensation 105368.00M 0.29M 0.46M 1.29M 0.18M
Other non cash items -263348.64M 1.80M 0.02M 0.00M 1.90M
Free cash flow -7164204.00M -5.59M -3.77M -5.52M -2.50M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACON
Aclarion Inc		 0.01
0.60%		 1.67 - - 106.39 0.63 101.77 -0.56
VEEV
Veeva Systems Inc Class A		 -1.60
0.53%		 302.12 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited		 -
-%		 144.00 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock		 6.32
8.31%		 82.37 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc		 0.30
5.27%		 5.99 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Aclarion Inc

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

8181 Arista Place, Broomfield, CO, United States, 80021

833 275 2266

https://www.aclarion.com

5

Name Title Year Born
Dr. Jeffrey John Thramann M.D. Exec. Chairman 1965
Mr. Brent Ness CEO, Pres & Director 1967
Mr. John Lorbiecki Chief Financial Officer 1964
Mr. Ryan Bond Chief Strategy Officer 1975
Dr. Jeffrey John Thramann M.D. Executive Chairman 1965
Mr. Ryan Bond Chief Strategy Officer 1973
Mr. Brent Ness CEO, President & Director 1967
Mr. John Lorbiecki Chief Financial Officer 1963
Mr. Ryan Bond Chief Strategy Officer 1972
Dr. Jeffrey John Thramann M.D. Executive Chairman 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…